Tobacco addiction: Implications for treatment and cancer prevention

Journal of the National Cancer Institute

Volumn 89, Issue 24, 1997, Pages 1852-1867

  Cinciripini, Paul M ^a   Hecht, Stephen S ^b   Henningfield, Jack E ^c   Manley, Marc W ^d   Kramer, Barnett S ^e  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e Div of Cancer Prev and Control

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CARCINOGEN; DOPAMINE UPTAKE INHIBITOR; NICOTINE GUM; PHENETHYL ISOTHIOCYANATE; PSYCHOTROPIC AGENT;

ADDICTION; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; FOOD AND DRUG ADMINISTRATION; HUMAN; LUNG CANCER; MEDICAL SOCIETY; MORTALITY; POLICY; PREVALENCE; REVIEW; SELF HELP; SMOKELESS TOBACCO; SMOKING; SMOKING CESSATION; TOBACCO;

EID: 0031470844     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.24.1852     Document Type: Review

References (160)

1. Kramer B. Introduction and organization of the ASCO/NCI conference on tobacco addiction. Presented at the American Society for Clinical Oncology and National Cancer Institute Symposium on Tobacco Addiction. Bethesda (MD), 1996.
2. Smoking and Health: Report of the Advisory Committee to the Surgeon General. Washington (DC): US Department of Health, Education, and Welfare, 1964.
3. Hoffmann D, Djordjevic MV, Fan J, Zang E, Glynn T, Connolly CN, et al. Five leading U.S. commercial brands of moist snuff in 1994: assessment of carcinogenic N-nitrosamines. J Natl Cancer Inst 1995;87:1862-9.
4. Fiore M. Trends in cigarette smoking in the United States. The epidemiology of tobacco use. Med Clin North Am 1992;76:289-303.
5. Smoking cessation during previous year among adults - United States, 1990 and 1991. MMWR Morb Mortal Wkly Rep 1993;42:504-7.
6. Collishaw N, Lopez A. The tobacco epidemic: a global public health emergency. World Health Organization, 1996.
7. Tobacco control: reducing cancer incidence and saving lives. American Society of Clinical Oncology. J Clin Oncol 1996;14:1961-3.
8. Glynn T. The worldwide epidemic of tobacco use: epidemiology and the benefits of quitting. Presented at the American Society for Clinical Oncology and National Cancer Institute Symposium on Tobacco Addiction. Bethesda (MD), 1996.
9. The Health Benefits of Smoking Cessation: a report of the Surgeon General. Rockville (MD): U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Centers for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 1990.
10. Surveillance for selected tobacco-use behaviors - United States. MMWR Morb Mortal Wkly Rep 1994;43:1-43.
11. Cigarette smoking among adults - United States, 1994. MMWR Morb Mortal Wkly Rep 1996;45:588-90.
12. Tobacco use and usual source of cigarettes among high school students -United States, 1995. MMWR Morb Mortal Wkly Rep 1996;45:413-8.
13. Johnston LD, O'Malley PM, Bachman JG. National survey results on drug use from the Monitoring the Future Study, 1975-1995. Vol I. Secondary school students. Rockville (MD): National Institute on Drug Abuse, NIH Publ No. 97-4139.
14. Use of smokeless tobacco among adults - United States, 1991 [published erratum appears in MMWR Morb Mortal Wkly Rep 1993;42:382]. MMWR Morb Mortal Wkly Rep 1993;42:263-6.
15. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1996;47:5-27.
16. Peto R, Lopez AD, Boreham J, Thun M, Heath C Jr. Mortality from tobacco in developed countries: indirect estimation from national vital statistics. Lancet 1996;39:1268-78.
17. Peto R. Smoking and death: the past 40 years and the next 40. BMJ 1994;309:937-9.
18. Yu JJ, Mattson ME, Boyd GM, Mueller MD, Shopland DR, Pechacek TF, et al. A comparison of smoking patterns in the People's Republic of China with the United States An impending health catastrophe in the middle kingdom [published erratum appears in JAMA 1990;264:3149]. JAMA 1990;264:1575-9.
19. Peto R, Lopez AD, Boreham J, Thun M, Heath C Jr, Doll R. Mortality from smoking worldwide. Br Med Bull 1996;52:12-21.
20. Reducing The Health Consequences of Smoking: 25 Years of Progress: a Report of the Surgeon General: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Centers for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 1989.
21. Howe GR, Jain M, Burch JD, Miller AB. Cigarette smoking and cancer of the pancreas: evidence from a population-based case-control study in Toronto, Canada. Int J Cancer 1991;47:323-8.
22. McLaughlin JK, Hrubec Z, Heineman EF, Blot WJ, Fraumeni JF Jr. Renal cancer and cigarette smoking in a 26-year followup of U.S. veterans. Public Health Rep 1990;105:535-7.
23. Whitmore WF. The treatment of invasive cancers of the bladder. J Urol 1988;94:337-43.
24. Mills PK, Newell GR, Beeson WL, Fraser GE, Phillips RL. History of cigarette smoking and risk of leukemia and myeloma: results from the Adventist health study. J Natl Cancer Inst 1990;82:1832-6.
25. Hecht SS. Carcinogen detoxification mechanisms and biomarkers of tobacco use. Presented at the American Society for Clinical Oncology and National Cancer Institute Symposium on Tobacco Addiction. Bethesda (MD), 1996.
26. Hoffmann D, Hecht SS. Advances in tobacco carcinogenesis. In: Cooper CS, Grover PL, editors. Handbook of experimental pharmacology. Heidelberg: Springer-Verlag, 1990:63-102.
27. Hecht SS, Hoffmann D. D 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a nicotine-derived tobacco-specific nitrosamine, and cancer of the lung and pancreas in humans. In: Brugge J. Curran T, Harlow E, McCormick F, editors. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press, 1991.
28. Polynuclear aromatic compounds, Part 1, Chemical, environmental and experimental data. IARC Monogr Eval Carcinog Risk Chem Hum 1983; 32:62-6.
29. Hecht SS. Recent studies on mechanisms of bioactivation and detoxification of 4-methylnitrosamino)-1(3-pyridyl)-1-butanone (NNK), a tobacco-specific lung carcinogen. Crit Rev Toxicol 1996;26:163-81.
30. Dipple A. Reactions of polycyclic aromatic hydrocarbons with DNA. IARC Sci Publ 1994;125:107-29.
31. Hecht SS, Peterson LA, Spratt TE. Tobacco-specific nitrosamines. IARC Sci Publ 1994;125:91-106.
32. Singer B, Essigmann JM. Site-specific mutagenesis: retrospective and prospective. Carcinogenesis 1991;12:949-55.
33. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
34. Rodenhuis S, Slebos RJ. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 1992;52(9 Suppl):2665s-2669s.
35. Minna JD. The molecular biology of lung cancer pathogenesis. Chest 1993;103:449s-456s.
36. Hecht SS, Hoffmann D, The relevance of tobacco-specific nitrosamines to human cancer. Cancer Surv 1989;8:273-94.
37. Perera FP. Molecular epidemiology: insights into cancer susceptibility, risk assessment, and prevention. J Natl Cancer Inst 1996;88:496-509.
38. Richie JP, Carmella SG, Muscat JE, Scott DG, Akerkar SA, Hecht SS. Differences in the urinary metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl-1-butanone in black and white smokers. Cancer Epidemiol Biomarkers Prev 1997;6: 783-90.
39. Landi MT, Zocchetti C, Bernucci I, Kadlubar FF, Tannenbaum S, Skipper P, et al. Cytochrome P4501A2: enzyme induction and genetic control in determining 4-aminobiphenyl-hemoglobin adduct levels. Cancer Epidemiol Biomarkers Prev 1996;5:693-8.
40. Hoffmann D, Djordjevic MV. Smokeless tobacco. Presented at the American Society for Clinical Oncology and National Cancer Institute Symposium on Tobacco Addiction. Bethesda (MD), 1996.
41. Armitage AK, Turner DM. Absorption of nicotine in cigarette and cigar smoke through the oral mucosa. Nature 1970;226:1231-2.
42. Assembly of Life Sciences: The Health Effects of Nitrate, Nitrite, and N-nitrosocompounds. Washington (DC): National Academy Press, 1981.
43. Hoffmann D, Aams JD, Brunnemann KD, Hecht SS. Assessment of tobacco-specific N-nitrosamines in tobacco products. Cancer Res 1979;39: 2505-9.
44. Hecht SS, Rivenson A, Braley J, DiBello J, Adams JD, Hoffmann D. Induction of oral cavity tumors in F344 rats by tobacco-specific nitrosamines and snuff. Cancer Res 1986;46:4162-6.
45. Kresty LA, Carmella SG, Borukhova A, Akerkar SA, Gopalakrishnan R, Harris RE, et al. Metabolites of a tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), in the urine of smokeless tobacco users: relationship between urinary biomarkers and oral leukoplakia. Cancer Epidemiol Biomarkers Prev 1996;5:521-5.
46. Hecht SS. Approaches to chemoprevention of lung cancer based on carcinogens in tobacco smoke. Environ Health Perspect 1997;105:955-63.
47. Hecht SS, Trushin N, Rigotty J, Carmella SG, Borukhova A, Akerkar S, et al. Complete inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced rat lung tumorigenesis and favorable modification of biomarkers by phenethyl isothiocyanate. Cancer Epidemiol Biomarkers Prev 1996;5:645-52.
48. Staretz ME, Hecht SS. Effects of phenethyl isothiocyanate on the tissue distribution of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and metabolites in F344 rats. Cancer Res 1995;55:5580-8.
49. Staretz ME, Foiles PG, Miglietta LM, Hecht SS. Evidence for an important role of DNA pyridylobutylation in rat ions carcinogenesis by 4-(methylnitrosamine)-1-(3-pyridyl)-1-butane: effects of dose and phenethyl isothiocynate. Cancer Res 1997;57:259-66.
50. Hecht SS, Chung FL, Richie JP Jr, Akerkar SA, Borukhova A, Skowronski L, et al. Effects of watercress consumption on metabolism of a tobacco-specific lung carcinogen in smokers. Cancer Epidemiol Biomarkers Prev 1995;4:877-84.
51. Estensen RD, Wattenberg LW. Studies of chemopreventive effects of myo-inositol on benzo[a]pyrene-induced neoplasia of the lung and forestomach of female A/J mice. Carcinogenesis 1993;14:1975-7.
52. Goodman CE, Omenn CS, CARET Co-Investigators and Staff: Carotene and retinol efficacy trial: lung cancer chemoprevention trial in heavy cigarette smokers and asbestos exposed workers. In: Newell GR, Hong WK, editors. The biology and prevention of aerodigestive tract cancers. New York: Plenum Press, 1992:197-208.
53. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocophenol Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994;330:1029-35.
54. Lippman SM, Spitz M, Trizna Z, Benner SE, Hong WK. Epidemiology. biology, and chemoprevention of aerodigestive cancer. Cancer 1994;74(9 Suppl): 19-27.
55. Spitz MR. Risk prediction. Presented at the American Society for Clinical Oncology and National Cancer Institute Symposium on Tobacco Addiction. Bethesda (MD), 1996.
56. Zang EA, Wynder EL. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst 1996;88:183-92.
57. Trizna Z, dayman GL, Spitz MR, Briggs KL, Goepfert H. Glutathione S-transferase genotypes as risk factors for head and neck cancer. Am J Surg 1995;170:499-501.
58. Spitz MR, Fueger JJ, Halabi S, Schantz SP, Sample D, Hsu TC. Mutagen sensitivity in upper aerodigestive tract cancer: a case-control analysis. Cancer Epidemiol Biomarkers Prev 1993;2:329-33.
59. Spitz MR, Hsu TC, Wu X, Fueger JJ, Amos CI, Roth JA. Mutagen sensitivity as a biological marker of lung cancer risk in African Americans. Cancer Epidemiol Biomarkers Prev 1995;4:99-103.
60. Strom SS, Wu S, Sigurdson AJ, Hsu TC, Fueger JJ, Lopez J, et al. Lung cancer, smoking patterns, and mutagen sensitivity in Mexican-Americans. J Natl Cancer Inst Monogr 1995;18:29-33.
61. Wu X, Hsu TC, Spitz MR. Mutagen sensitivity exhibits a dose-response relationship in case-control studies. Cancer Epidemiol Biomarkers Prev 1996;5:577-8.
62. Cloos J, Spitz MR, Schantz SP, Hsu TC, Zhang ZF, Tobi H, et al. Genetic susceptibility to head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88:530-5.
63. Jin X, Wu X, Roth JA, Amos CI, King TM, Branch C, et al. Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis 1995;16:2205-8.
64. Henningfield JE, Schuh LM, Jarvik ME. Pathophysiology of tobacco dependence. In: The Fourth Generation of Progress, Psychopharmacology: The Fourth Generation of Progress, New York: Raven Press, 1995.
65. Henningfield JE. Nicotine medications for smoking cessation. N Engl J Med 1995;333:1196-203.
66. Preventing Tobacco Use Among Young People: a report of the Surgeon General. Atlanta (GA): U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 1994.
67. Giovino GA, Henningfield JE, Tomar SL, Escobedo LG, Slade J. Epidemiology of tobacco use and dependence. Epidemiol Rev 1995;17:48-65.
68. Food and Drug Administration: Regulation of cigarettes and smokeless tobacco under the Federal Food, Drug and Cosmetic Act. Federal Register, Wednesday, August 28, 1996.
69. Breslau N, Kilbey MM, Andreski P. Nicotine dependence and major depression: new evidence from a prospective investigation. Arch Gen Psychiatry 1993;50:31-5.
70. Anthony J, Warner AJ, Kessler R. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the national comorbidity survey. Exp Clin Pharmacol 1994; 2:244-68.
71. Benowitz NL. Chemistry of nicotine: tobacco as a nicotine delivery system. Presented at the American Society for Clinical Oncology and National Cancer Institute Symposium on Tobacco Addiction. Bethesda (MD), 1996.
72. The Health Consequences of Smoking: Nicotine Addiction - a report of the Surgeon General. Rockville (MD): U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Centers for Health Promotion and Education, Office on Smoking and Health, 1988.
73. Gori GB, Benowitz NL, Lynch CJ. Mouth versus deep airways absorption of nicotine in cigarette smokers. Pharmacol Pharmacol Biochem Behav 1986;25:1181-4.
74. Henningfield JE, Stapleton JM, Benowitz NL, Grayson RF, London ED, et al. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend 1993;33:23-9.
75. Henningfield JE, Kozlowski LT, Benowitz NL. A proposal to develop meaningful labeling for cigarettes. JAMA 1994;272:312-4.
76. Benowitz NL, Jacob P 3d, Denaro C, Jenkins R. Stable isotope studies of nicotine kinetics and bioavailability. Clin Pharmacol Ther 1991;270-77.
77. Swedberg MD, Henningfield JE, Golderg SR. Nicotine dependency: animal studies. In: Wonnacott S, Rusell MA, Stolerman IP, editors. Nicotine psychopharmacology: molecular, cellular and behavioral aspects. Oxford, Oxford Univ Press, 1990:38-76.
78. Shiftman S, Paty JA, Gnys M, Kassel JD, Elash C. Nicotine withdrawal in chippers and regular smokers: subjective and cognitive effects. Health Psychol 1995;14:301-9.
79. Pomerleau OF, Pomerleau CS. Neuroregulators and the reinforcement of smoking: towards a biobehavioral explanation. Neurosci Biobehav Rev 1984;8:503-13.
80. Warburton DM, Rusted JM, Fowler J. Comparison of the attentional and consolidation hypotheses for the facilitation of memory by nicotine. Psychopharmacology 1992;108:443-7.
81. Gilbert DG. Smoking individual differences, psychopathology and emotion. In: Baker KP, Seltzer H, editors. The series in health psychology and behavioral medicine. Washington (DC): Taylor & Francis, 1995.
82. Stolerman IP, Mirza NR, Shoaib M. Nicotine psychopharmacology: addiction, cognition and neuroadaptation. Med Res Rev 1995;15:47-72.
83. Grenhoff J, Svensson TH. Pharmacology of nicotine. Br J Addict 1989; 84:477-92.
84. Anderson IM, Tomenson BM. The efficacy of selective serotonin reupke inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 1994;8:238-49.
85. Henningfield JE, Keenan RM, Clarke P. Nicotine. In: Schuster C, Kuhar M, editors. Pharmacological aspects of drug dependence: toward an integrated neurobehavioral approach. Berlin: Springer-Verlag. 1996:271-314.
86. Pomerleau OF, Collins AC, Shiffman S, Pomerleau CS. Why some people smoke and others do not: new perspectives. J Consult Clin Psychol 1993; 61:723-1.
87. Strategies to Control Tobacco Use in The United States. Rockville (MD): U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Centers for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 1991.
88. McNeill AD, Jarvis MJ, Stapleton JA, West RJ, Bryant A. Nicotine intake in young smokers: longitudinal study of saliva cotinine concentrations. Am J Public Health 1989;79:172-5.
89. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington (DC). American Psychiatric Association, 1994.
90. Casey K. If only I could quit: Becoming a Nonsmoker. Center City (MN): Hazelden Books, 1987.
91. Snyder FR, Davis FC, Henningfield JE. The tobacco withdrawal syndrome: performance decrements assessed on a computerized test battery. Drug Alcohol Depend 1989;97:17-22.
92. Pickworth WB, Herning RI, Henningfield JE. Spontaneous EEG changes during tobacco abstinence and nicotine substitution in human volunteers. J Pharmacol Exp Ther 1989;251:976-82.
93. Hall SM, Ginsberg D, Jones RT. Smoking cessation and weight gain. J Consult Clin Psychol 1986;54:342-6.
94. Hatsukami D, LaBounty L, Hughes J, Laine D. Effects of tobacco abstinence on food intake among cigarette smokers. Health Psychol 1993;12: 499-502.
95. Hughes JR, Higgins ST, Hatsukami D. Effects of abstinence from tobacco. In: Kozlowski LT, Annis HM, Cappell HD, Glaser FB, Goodstadt MS, Israel Y, et al., editors. Research advances in alcohol and drug problems. New York: Plenum Press, 1990:317-98.
96. Cinciripini PM. Smoking cessation and depressed mood: recognition and implications for treatment. Present at the American Society of Clinical Oncology and National Cancer Institute Symposium on Tobacco Addiction. Bethesda (MD): 1996.
97. Glassman A, Helzer JE, Covey LS, Cottler LB, Stetner F, Tipp JE, et al. Smoking, smoking cessation, and major depression. JAMA 1990;264: 1546-9.
98. Anda RF, Williamson DF, Escobedo LG, Mast EE, Giovino GA, Remington PL. Depression and the dynamics of smoking. A national perspective. JAMA 1990;264:1541-5.
99. Breslau N, Kilbey M, Andreski P. Nicotine dependence, major depression, and anxiety in young adults. Arch Gen Psychiatry 1991;48:1069-74.
100. Kendler KS, Neale MC, Mac-Lean CJ, Heath AC, Eaves LJ, Kessler RC. Smoking and major depression. A causal analysis. Arch Gen Psychiatry 1993;50:36-43.
101. Breslau N, Kilbey MM, Andreski P. Nicotine withdrawal symptoms and psychiatric disorders: findings from an epidemiologic study of young adults. Am J Psychiatry 1992;149:464-9.
102. Covey LS, Glassman AH, Stetner F. Depression and depressive symptoms in smoking cessation. Compr Psychiatry 1990;31:350-4.
103. Glassman AH, Stetner F, Walsh BT, Raizman PS, Fleiss JL, Cooper TB, et al. Heavy smokers, smoking cessation, and clonidine. Results of a double-blind, randomized trial. JAMA 1988;259:2863-6.
104. Rosales TA. DSM-III-R nicotine dependence in the national comorbidity survey (NCS). Presented at the Society for Research on Nicotine and Tobacco (SRNT) 2nd annual scientific conference. Washington (DC), 1996.
105. Negative moods as correlates of smoking and heavier drinking: Implications for health promotion. Advance Data 1993;236:1-12.
106. Brandon TH, Tiffany ST, Obremski KM, Baker TB. Postcessation cigarette use: the process of relapse. Addict Behav 1990;15:105-14.
107. Shiftman S. Relapse following smoking cessation: a situational analysis. J Counsult Clin Psychol 1982;50:71-86.
108. Shiffman S. Cognitive antecedents and sequelae of smoking relapse crises. J Appl Soc Psychol 1984;14:296-309.
109. Shiftman S, Paty JA, Gnys M, Kassel JA, Hickcox M. First lapses to smoking: within-subjects analysis of real-time reports. J Consult Clin Psychol 1996;64:366-79.
110. Wetter DW, Smith SS, Kenford SL, Jorenby DE, Fiore MC, Hurt RD, et al. Smoking outcome expectancies: factor structure, predictive validity, and discriminant validity. J Abnorm Psychol 1994;103:801-11.
111. Hughes JR. Tobacco withdrawal in self-quitters. J Consult Clin Psychol 1992;60:689-97.
112. West RJ, Hajek P, Belcher M. Severity of withdrawal symptoms as a predictor of outcome of an attempt to quit smoking. Psychol Med 1989; 19:981-5.
113. Piasecki TM, Kenford SL, Smith SS, Fiore MC, Baker TB. Listening to nicotine: negative affect and the smoking withdrawal conundrum. Psycholog Sci 1977;8:184.
114. Cigarette smoking among adults - United States, 1993. MMWR Morbid Mortal Wkly Rep 1994;43:925-30.
115. Fiore MC, Novotny TE, Pierce JP, Ginvino GA, Hatziandreu EJ, Newcomb PA, et al. Methods used to quit smoking in the United States. JAMA 1990;263:2760-5.
116. Hollis JF, Lichtenstein E, Vogt TM. Nurse-assisted counseling for smokers in primary care. Ann Intern Med 1993:521-5.
117. DeClemente CC, Velicer WF, Hughes SL. An empirical typology of subjects within stage of change. Addict Behav 1995;20:299-320.
118. Cohen S, Lichtenstein E, Prochaska JO, Rossi JS, Gritz ER, Carr CR, et al. Debunking myths about self-quitting. Evidence from ten prospective studies of persons who attempt to quit smoking by themselves. Am Psychol 1989;4:1355-65.
119. Henningfield JE, Vocci F, Sachs DPL. Smoking cessation medications. Presented at the American Society for Clinical Oncology and National Cancer Institute Symposium on Tobacco Addiction. Bethesda (MD), 1996.
120. Henningfield JE, Radzius A, Cone EJ. Estimation of available nicotine content of six smokeless tobacco products. Tobacco Control 1005;1: 57-61.
121. Benowitz NL. Nicotine replacement therapy. What has been accomplished - can we do better? [published erratum appears in Drugs 1993; 45:736]. Drugs 1993;45:157-70.
122. Hughes JR. American Psychiatric Association: practice guideline for the treatment of patients with nicotine dependence. American Journal of Psychiatry. October 1996, Suppl 153, 1996.
123. Fiore MC, Bailey WC, Cohen SJ, et al. Smoking Cessation. Clinical Practice Guideline No 18. Rockville (MD): U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, AHCPR Publ No. 96-0692 April 1996.
124. Fiore MC, Smith SS, Jorenby DE, Baker TB. The effectiveness of the nicotine patch for smoking cessation. JAMA 1994;271:1940-7.
125. Jorenby DE, Fiore MC, Hurt RD, Offord KP, Croghan IJ, Haves JT, et al. Varying nicotine patch dose and type of smoking cessation counseling. JAMA 1995;74:1347-52.
126. Cepeda-Benito A. A meta-analytical review of the efficacy of nicotine chewing gum in smoking treatment programs. J Consult Clin Psychol 1993;61:822-30.
127. Sachs DP. Effectiveness of the 4-mg dose of nicotine polacrilex for the initial treatment of high-dependent smokers. Arch Intern Med 1996;155: 1973-80.
128. Zelman DC, Brandon TH, Jorenby DE, Baker TB. Measures of affect and nicotine dependence predict differential response to smoking cessation treatments. J Consult Clin Psychol 1992;60:943-52.
129. Brandon TH, Copeland AL, Saper ZL. Programmed therapeutic messages as a smoking treatment adjunct: reducing the impact of negative affect. Health Psychol 1995;14:41-7.
130. Hall SM, Munoz RF, Reus VI. Cognitive-behavioral intervention increases abstinence rates for depressive-history smokers. J Consult Clin Psychol 1994;62:141-6.
131. Hall SM, Munoz RF, Reus VI, Sees KL, Duncan C, Humfleet GL, et al. Mood management and nicotine gum in smoking treatment: a therapeutic-contact and placebo-controlled study. J Consult Clin Psychol 1996;64: 1003-9.
132. Kinnunen T, Doheru K, Militello FS, Garvey AJ. Depression and smoking cessation: characteristics of depressed smokers and effects of nicotine replacement. J Consult Clin Psychol 1996;64:791-8.
133. Cinciripini PM, Lapitsky LG, Wallfisch A, et al. Smoking cessation and depressed mood: does transdermal nicotine replacement enhance success? Presented at the Society for Behavioral Medicine. San Diego (CA). 1995.
134. Kenford SL, Fiore MC, Jorenby DE, Smith SS, Wetter D, Baker TB. Predicting smoking cessation. Who will quit with and without the nicotine patch/ JAMA 1994;271:589-94.
135. Cinciripini PM, Cinciripini LG, Wallfisch A, Haque W, Van Vunakis H. Behavior therapy and the transdermal nicotine patch: effects on cessation outcome, affect, and coping. J Consult Clin Psychol 1996;64:314-23.
136. Perkins KA. Sex differences in nicotine versus non nicotine reinforcement at determinants of tobacco smoking. Exp Clin Psychopharmacol 1996;4: 1-12.
137. Niaura R, Goldstein M, Depue J, et al. Fluoxetine, symptoms of depression, and smoking cessation. Presented at the annual meeting of the Society of Behavioral Medicine, 1995.
138. Cinciripini PM, Cinciripini LG, Seay S, Wallfisch A, Meyer WJ 3rd, Van Vunakis H. A placebo-controlled evaluation of the effects of buspirone on smoking cessation: differences between high-and low-anxiety smokers [published erratum appears in J Clin Psychopharmacol 1995;15:408]. J Clin Psychopharmacol 1995;15:182-91.
139. Schneider NG, Olmstead R, Mody FV, Doan K, Franzon M, Jarvik ME, et al. Efficacy of a nicotine nasal spray in smoking cessation: a placebocontrolled, double-blind trial. Addiction 1995;90:1671-82.
140. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnson JA, Dale LC, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997;17:1195-203.
141. Rose JE, Sampson A, Levin ED, Henningfield JE. Mecamylamine increases nicotine preference and attentuates nicotine discrimination. Pharmacol Biochem Behav 1989;32:933-8.
142. Rose JE, Behm FM, Westman EC, Levin ED, Stein RM, Ripka GV. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin Pharmacol Ther 1994;56:86-99.
143. Keenan RM, Hatsukami DK, Pentel PR, Thompson TN, Grillo MA. Pharmacodynamic effects of cotinine in abstinent cigarette smokers. Clin Pharmacol Ther 1994;55:581-590.
144. Keenan RM, Jarvik ME, Henningfield JE. Management of nicotine dependence and withdrawal. In: Miller NS, editor. Principles of addiction medicine. Chevy Chase (MD): American Society of Addiction Medicine, 1994:1-14.
145. Slade J. Nicotine addiction: principles and management. In: Orleans CT, editor. Nicotine delivery devices. Oxford: Oxford Univ Press, 1993:3-23.
146. Freedman AM. How tobacco giant doctors snuff brands to boost their 'kick.' Wall Street Journal 1994 October 26, Sect A: 1.
147. Fiore MC. AHCPR smoking cessation guidelines. Presented at the American Society for Clinical Oncology and National Cancer Institute Symposium on Tobacco Addiction. Bethesda (MD), 1996.
148. Fiore MC, Jorenby DE, Schensky AE, Smith SS, Bauer RR, Baker TB. Smoking status as the new vital sign: effect on assessment and intervention in patients who smoke. Mayo Clinic Proc 1995;70:209-13.
149. Strecher VJ. Tailoring smoking cessation programs to the individual. Presented at the American Society for Clinical Oncology and National Cancer Institute Symposium on Tobacco Addiction. Bethesda (MD). 1996.
150. Curry SJ, Wagner EH, Grothaus LC. Evaluation of intrinsic and extrinsic motivation interventions with a self-help smoking cessation program. J Consult Clin Psychol 1991;59:318-24.
151. Curry SJ, McBride C, Grothaus LC, Louie D, Wagner EH. Self-help with nonvolunteer smokers: a randomized trial of self-help materials, personalized feedback, and telephone counseling with nonvolunteer smokers. J Consult Clin Psychol 1995;63:1005-14.
152. Strecher VJ, Kreuter M, Boer D, Kobrin S, Hospers HJ, Skinner CS. The effects of computer-tailored smoking cessation messages in family practice settings. J Family Pract 1994;39:262-70.
153. Prochaska JO, DiClmente CC, Velicer WF, Rossi JS. Standardized, individualized, interactive, and personalized self-help programs for smoking cessation. Health Psychol 1993;12:399-405.
154. Orleans CT, Boyd RN, Noll E, Crosette L, Glassman B, Intervening through a prescription benefit plan for nicotine patch users. Presented at the Society for Behavioral Medicine. Washington (DC), 1996.
155. Green SB. Behavioral study results: COMMIT. Presented at the American Society for Clinical Oncology and National Cancer Institute Symposium on Tobacco Addiction. Bethesda (MD), 1996.
156. Community Intervention Trial for Smoking Cessation (COMMIT): summary of design and intervention. COMMIT Research Group. J Natl Cancer Inst 1991;83:1620-28.
157. Community Intervention Trial for Smoking Cessation (COMMIT): I. Cohort results from a four-year community intervention. Am J Public Health 1995;85:183-92.
158. The COMMIT Research Group: Community Intervention Trial for Smoking Cessation (COMMIT): II. Changes in adult cigarette smoking prevalence. Am J Public Health 1995;85:193-200.
159. Kessler D. Evidence that nicotine can be considered a drug. Presented at the American Society for Clinical Oncology and National Cancer Institute Symposium on Tobacco Addiction. Bethesda (MD), 1996.
160. Koop E. National strategies to combat tobacco use and addiction. Presented at the American Society for Clinical Oncology and National Cancer Institute Symposium on Tobacco Addiction. Bethesda (MD), 1996.